Utility of molecular testing for related retinal dystrophies

Eedy Mezer, Joanne Sutherland, Stephanie Goei, Elise Héon, Alex V. Levin

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Background: The purpose of this study was to describe our experience with the clinical effects of molecular genetic testing for retinitis pigmentosa (RP) and related retinal dystrophies. Methods: Chart review of 303 consecutive patients with retinal dystrophies was done when blood was sent for molecular genetic testing between 1993 and 2001. Phenotype information was retrieved for patients with identified mutations. The yield of positive and clinically useful results was assessed. Results: Participants comprised 35 patients with Leber congenital amaurosis, 18 with Usher syndrome, and 250 with isolated RP or other retinal dystrophies. Of these 303 participants, 203 (67%) received positive or negative results of molecular testing for an average of 2.7 genes. Positive results were available in 19 patients after an average time interval of 38 ± 22 months (median 33 months, range 1-89 months). No results were received for 84 (28%) patients. In 16 (5%) cases, patients received partial results. Only 19 (6%) patients were found to have sequence changes in RHO, RDS, CRB1, or USH2A, 2 of which were thought to be disease-causing. Only 2 sequence changes were previously documented mutations, but several other novel changes were suspected to be disease-causing mutations also. Interpretation: Molecular testing was helpful only in the minority of cases, largely because of a lack of availability, as well as the complexity of the molecular genetics of RP. Improvements in funding, infrastructure, and molecular knowledge will be necessary to improve the transformation of molecular genetic testing into a clinically relevant bedside tool.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalCanadian Journal of Ophthalmology
Volume41
Issue number2
DOIs
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Retinal Dystrophies
Retinitis Pigmentosa
Molecular Biology
Genetic Testing
Mutation
Leber Congenital Amaurosis
Usher Syndromes
Phenotype

Keywords

  • Molecular testing
  • Retinal dystrophy
  • Retinitis pigmentosa

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Utility of molecular testing for related retinal dystrophies. / Mezer, Eedy; Sutherland, Joanne; Goei, Stephanie; Héon, Elise; Levin, Alex V.

In: Canadian Journal of Ophthalmology, Vol. 41, No. 2, 01.01.2006, p. 190-196.

Research output: Contribution to journalReview article

Mezer, Eedy ; Sutherland, Joanne ; Goei, Stephanie ; Héon, Elise ; Levin, Alex V. / Utility of molecular testing for related retinal dystrophies. In: Canadian Journal of Ophthalmology. 2006 ; Vol. 41, No. 2. pp. 190-196.
@article{591b7c0e0c3548f8b2ed3379253bedaa,
title = "Utility of molecular testing for related retinal dystrophies",
abstract = "Background: The purpose of this study was to describe our experience with the clinical effects of molecular genetic testing for retinitis pigmentosa (RP) and related retinal dystrophies. Methods: Chart review of 303 consecutive patients with retinal dystrophies was done when blood was sent for molecular genetic testing between 1993 and 2001. Phenotype information was retrieved for patients with identified mutations. The yield of positive and clinically useful results was assessed. Results: Participants comprised 35 patients with Leber congenital amaurosis, 18 with Usher syndrome, and 250 with isolated RP or other retinal dystrophies. Of these 303 participants, 203 (67{\%}) received positive or negative results of molecular testing for an average of 2.7 genes. Positive results were available in 19 patients after an average time interval of 38 ± 22 months (median 33 months, range 1-89 months). No results were received for 84 (28{\%}) patients. In 16 (5{\%}) cases, patients received partial results. Only 19 (6{\%}) patients were found to have sequence changes in RHO, RDS, CRB1, or USH2A, 2 of which were thought to be disease-causing. Only 2 sequence changes were previously documented mutations, but several other novel changes were suspected to be disease-causing mutations also. Interpretation: Molecular testing was helpful only in the minority of cases, largely because of a lack of availability, as well as the complexity of the molecular genetics of RP. Improvements in funding, infrastructure, and molecular knowledge will be necessary to improve the transformation of molecular genetic testing into a clinically relevant bedside tool.",
keywords = "Molecular testing, Retinal dystrophy, Retinitis pigmentosa",
author = "Eedy Mezer and Joanne Sutherland and Stephanie Goei and Elise H{\'e}on and Levin, {Alex V.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1139/I06-007",
language = "English (US)",
volume = "41",
pages = "190--196",
journal = "Canadian Journal of Ophthalmology",
issn = "0008-4182",
publisher = "Canadian Ophthalmological Society",
number = "2",

}

TY - JOUR

T1 - Utility of molecular testing for related retinal dystrophies

AU - Mezer, Eedy

AU - Sutherland, Joanne

AU - Goei, Stephanie

AU - Héon, Elise

AU - Levin, Alex V.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Background: The purpose of this study was to describe our experience with the clinical effects of molecular genetic testing for retinitis pigmentosa (RP) and related retinal dystrophies. Methods: Chart review of 303 consecutive patients with retinal dystrophies was done when blood was sent for molecular genetic testing between 1993 and 2001. Phenotype information was retrieved for patients with identified mutations. The yield of positive and clinically useful results was assessed. Results: Participants comprised 35 patients with Leber congenital amaurosis, 18 with Usher syndrome, and 250 with isolated RP or other retinal dystrophies. Of these 303 participants, 203 (67%) received positive or negative results of molecular testing for an average of 2.7 genes. Positive results were available in 19 patients after an average time interval of 38 ± 22 months (median 33 months, range 1-89 months). No results were received for 84 (28%) patients. In 16 (5%) cases, patients received partial results. Only 19 (6%) patients were found to have sequence changes in RHO, RDS, CRB1, or USH2A, 2 of which were thought to be disease-causing. Only 2 sequence changes were previously documented mutations, but several other novel changes were suspected to be disease-causing mutations also. Interpretation: Molecular testing was helpful only in the minority of cases, largely because of a lack of availability, as well as the complexity of the molecular genetics of RP. Improvements in funding, infrastructure, and molecular knowledge will be necessary to improve the transformation of molecular genetic testing into a clinically relevant bedside tool.

AB - Background: The purpose of this study was to describe our experience with the clinical effects of molecular genetic testing for retinitis pigmentosa (RP) and related retinal dystrophies. Methods: Chart review of 303 consecutive patients with retinal dystrophies was done when blood was sent for molecular genetic testing between 1993 and 2001. Phenotype information was retrieved for patients with identified mutations. The yield of positive and clinically useful results was assessed. Results: Participants comprised 35 patients with Leber congenital amaurosis, 18 with Usher syndrome, and 250 with isolated RP or other retinal dystrophies. Of these 303 participants, 203 (67%) received positive or negative results of molecular testing for an average of 2.7 genes. Positive results were available in 19 patients after an average time interval of 38 ± 22 months (median 33 months, range 1-89 months). No results were received for 84 (28%) patients. In 16 (5%) cases, patients received partial results. Only 19 (6%) patients were found to have sequence changes in RHO, RDS, CRB1, or USH2A, 2 of which were thought to be disease-causing. Only 2 sequence changes were previously documented mutations, but several other novel changes were suspected to be disease-causing mutations also. Interpretation: Molecular testing was helpful only in the minority of cases, largely because of a lack of availability, as well as the complexity of the molecular genetics of RP. Improvements in funding, infrastructure, and molecular knowledge will be necessary to improve the transformation of molecular genetic testing into a clinically relevant bedside tool.

KW - Molecular testing

KW - Retinal dystrophy

KW - Retinitis pigmentosa

UR - http://www.scopus.com/inward/record.url?scp=33646249398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646249398&partnerID=8YFLogxK

U2 - 10.1139/I06-007

DO - 10.1139/I06-007

M3 - Review article

C2 - 16767206

AN - SCOPUS:33646249398

VL - 41

SP - 190

EP - 196

JO - Canadian Journal of Ophthalmology

JF - Canadian Journal of Ophthalmology

SN - 0008-4182

IS - 2

ER -